Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | PDE5A | O76074 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6090982 | 1.00 | KDM4E (0.37) | KDM4EGAAALDH1A1PDE5AHPGD | |
| SCHEMBL6091283 | 0.93 | KDM4E (0.37) | KDM4EGAAALDH1A1PDE5AHPGD | |
| SCHEMBL6091280 | 0.93 | KDM4E (0.37) | KDM4EGAAALDH1A1PDE5AHPGD | |
| SCHEMBL6089511 | 0.90 | KDM4E (0.38) | KDM4EGAAALDH1A1HPGDMAPT | |
| SCHEMBL6089506 | 0.90 | KDM4E (0.38) | KDM4EGAAALDH1A1HPGDMAPT | |
| SCHEMBL6091975 | 0.88 | PARP1 (0.35) | KDM4EALDH1A1HPGDCREBBP | |
| SCHEMBL6091971 | 0.88 | PARP1 (0.35) | KDM4EALDH1A1HPGDCREBBP | |
| SCHEMBL6090687 | 0.88 | KDM4E (0.46) | KDM4EGAAALDH1A1HPGDMAPT | |
| SCHEMBL6091358 | 0.87 | KDM4E (0.39) | KDM4EGAAALDH1A1PDE5AHPGD | |
| SCHEMBL6091162 | 0.83 | PARP1 (0.42) | KDM4EGAAALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1582520-A1 | NOVEL PARP INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | PARP1, PARP2, PARP11 | KDM4E 812/4885GAA 2522/4885ALDH1A1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.